SK279659B6 - Použitie riluzolu - Google Patents

Použitie riluzolu Download PDF

Info

Publication number
SK279659B6
SK279659B6 SK1076-95A SK107695A SK279659B6 SK 279659 B6 SK279659 B6 SK 279659B6 SK 107695 A SK107695 A SK 107695A SK 279659 B6 SK279659 B6 SK 279659B6
Authority
SK
Slovakia
Prior art keywords
riluzole
pharmaceutically acceptable
compositions
preparation
administration
Prior art date
Application number
SK1076-95A
Other languages
English (en)
Slovak (sk)
Other versions
SK107695A3 (en
Inventor
Anne Bousseau
Adam Doble
Erik Louvel
Original Assignee
Rhone-Poulenc Rorer S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer S.A. filed Critical Rhone-Poulenc Rorer S.A.
Publication of SK107695A3 publication Critical patent/SK107695A3/sk
Publication of SK279659B6 publication Critical patent/SK279659B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SK1076-95A 1993-03-05 1994-02-25 Použitie riluzolu SK279659B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9302568A FR2702148B1 (fr) 1993-03-05 1993-03-05 Application d'anticonvulsivants dans le traitement du neuro-sida.
PCT/FR1994/000208 WO1994020103A1 (fr) 1993-03-05 1994-02-25 Application du riluzole dans le traitement du neuro-sida

Publications (2)

Publication Number Publication Date
SK107695A3 SK107695A3 (en) 1996-06-05
SK279659B6 true SK279659B6 (sk) 1999-02-11

Family

ID=9444690

Family Applications (3)

Application Number Title Priority Date Filing Date
SK1074-95A SK107495A3 (en) 1993-03-05 1994-02-25 Use of lamotrigine for treating aids-related neural disorders
SK1076-95A SK279659B6 (sk) 1993-03-05 1994-02-25 Použitie riluzolu
SK1075-95A SK107595A3 (en) 1993-03-05 1994-02-25 Use of anticonvulsive agents for treating aids-related neural disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SK1074-95A SK107495A3 (en) 1993-03-05 1994-02-25 Use of lamotrigine for treating aids-related neural disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
SK1075-95A SK107595A3 (en) 1993-03-05 1994-02-25 Use of anticonvulsive agents for treating aids-related neural disorders

Country Status (23)

Country Link
US (2) US5629312A (es)
EP (3) EP0687177B1 (es)
JP (3) JPH08507509A (es)
KR (3) KR960700721A (es)
AT (2) ATE147981T1 (es)
AU (3) AU675118B2 (es)
CA (3) CA2154572C (es)
CZ (3) CZ226095A3 (es)
DE (2) DE69427344T2 (es)
DK (2) DK0687177T3 (es)
ES (2) ES2157252T3 (es)
FR (1) FR2702148B1 (es)
GR (2) GR3022356T3 (es)
HU (3) HU217132B (es)
IL (3) IL108845A0 (es)
NO (3) NO953372L (es)
PL (3) PL310475A1 (es)
PT (1) PT687176E (es)
RU (1) RU2157205C2 (es)
SK (3) SK107495A3 (es)
UA (1) UA41355C2 (es)
WO (3) WO1994020103A1 (es)
ZA (2) ZA941530B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866597A (en) * 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
DE19603984A1 (de) * 1996-02-05 1997-08-07 Bayer Ag Granulate von Triazinen
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US5922746A (en) * 1997-03-27 1999-07-13 Allergan Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
GB9721497D0 (en) * 1997-10-09 1997-12-10 Ciba Geigy Ag Organic compounds
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
FR2774908B1 (fr) * 1998-02-17 2000-06-23 Centre Nat Rech Scient Utilisation d'inhibiteur de la liberation du glutamate dans le traitement de l'ischemie retinienne
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6239156B1 (en) * 1999-04-29 2001-05-29 Centre National De La Recherche Scientifique Cnrs Method for the prevention of ischemic spinal cord injury caused by aortic crossclamping
US7479498B2 (en) * 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
GB9930058D0 (en) 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US6207179B1 (en) * 2000-05-18 2001-03-27 Phoenix Scientific, Inc. Parasiticidal formulation for animals and a method of making this formulation
CA2471666C (en) 2004-06-18 2009-10-13 Apotex Pharmachem Inc. An improved process for the preparation of oxcarbazepine and related intermediates
EP1874353A1 (en) * 2005-04-05 2008-01-09 Yale University Glutamate modulating agents in the treatment of mental disorders
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
FR2910811B1 (fr) * 2007-01-03 2009-07-10 Ass Pour Le Dev De La Biothera Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
SI3220891T1 (sl) * 2014-11-21 2020-02-28 Biohaven Therapeutics Ltd. Podjezična formulacija riluzola
CA3209488A1 (en) * 2021-02-24 2022-09-01 Jacob BONTA Foaming evaporator coil cleaner

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
US4918090A (en) * 1988-01-25 1990-04-17 Warner-Lambert Company Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents
EP0435826A1 (de) * 1989-12-27 1991-07-03 Ciba-Geigy Ag Intravenöse Lösungen für Status Epilepticus
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
JPH07308499A (ja) * 1994-05-20 1995-11-28 Brother Ind Ltd 衣類乾燥機

Also Published As

Publication number Publication date
GR3022356T3 (en) 1997-04-30
JPH08507507A (ja) 1996-08-13
DE69401577T2 (de) 1997-05-15
IL108846A0 (en) 1994-06-24
IL108845A0 (en) 1994-06-24
EP0687179A1 (fr) 1995-12-20
UA41355C2 (uk) 2001-09-17
NO953372D0 (no) 1995-08-28
HU9502584D0 (en) 1995-11-28
NO953371L (no) 1995-08-28
HUT73433A (en) 1996-07-29
WO1994020110A1 (fr) 1994-09-15
US5624945A (en) 1997-04-29
WO1994020108A1 (fr) 1994-09-15
HU9502583D0 (en) 1995-11-28
CZ226195A3 (en) 1995-12-13
NO307687B1 (no) 2000-05-15
AU675118B2 (en) 1997-01-23
HU217132B (hu) 1999-11-29
KR100318168B1 (ko) 2002-06-20
DE69427344T2 (de) 2002-04-25
EP0687176A1 (fr) 1995-12-20
EP0687176B1 (fr) 2001-05-30
PL310475A1 (en) 1995-12-11
CA2154572A1 (fr) 1994-09-15
KR960700721A (ko) 1996-02-24
ATE201597T1 (de) 2001-06-15
AU675119B2 (en) 1997-01-23
DK0687176T3 (da) 2001-07-30
DE69427344D1 (de) 2001-07-05
CA2154571A1 (fr) 1994-09-15
JPH08507509A (ja) 1996-08-13
CZ226095A3 (en) 1995-12-13
CZ285339B6 (cs) 1999-07-14
US5629312A (en) 1997-05-13
ZA941530B (en) 1994-10-06
FR2702148B1 (fr) 1995-04-07
CZ284423B6 (cs) 1998-11-11
FR2702148A1 (fr) 1994-09-09
CZ225995A3 (en) 1995-12-13
EP0687177B1 (fr) 1997-01-22
AU6143794A (en) 1994-09-26
GR3035957T3 (en) 2001-08-31
ZA941525B (en) 1994-11-09
CA2154572C (fr) 2006-06-06
ES2096455T3 (es) 1997-03-01
JP3578174B2 (ja) 2004-10-20
HUT73434A (en) 1996-07-29
EP0687177A1 (fr) 1995-12-20
ATE147981T1 (de) 1997-02-15
WO1994020103A1 (fr) 1994-09-15
SK107695A3 (en) 1996-06-05
KR960700723A (ko) 1996-02-24
NO953371D0 (no) 1995-08-28
ES2157252T3 (es) 2001-08-16
NO953370L (no) 1995-08-28
NO953372L (no) 1995-08-28
SK107595A3 (en) 1996-06-05
DE69401577D1 (de) 1997-03-06
IL108844A0 (en) 1994-06-24
HU9502585D0 (en) 1995-11-28
CA2154573A1 (fr) 1994-09-15
PT687176E (pt) 2001-09-28
RU2157205C2 (ru) 2000-10-10
JPH08507508A (ja) 1996-08-13
NO953370D0 (no) 1995-08-28
DK0687177T3 (da) 1997-02-10
IL108844A (en) 1998-01-04
PL310474A1 (en) 1995-12-11
AU6143994A (en) 1994-09-26
SK107495A3 (en) 1996-06-05
KR960700716A (ko) 1996-02-24
PL310476A1 (en) 1995-12-11
AU6143894A (en) 1994-09-26

Similar Documents

Publication Publication Date Title
SK279659B6 (sk) Použitie riluzolu
DE69329397T2 (de) Vervendung von K-252a Derivaten zur Förderung der Funktion eines stritialen Neurons
DE69400799T2 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69327330T2 (de) Verfahren zum bekämpfen der pneumocystis carinii pneumonie und dafür verwendbare verbindungen
SK279046B6 (sk) Použitie 2-amino-6-trifluórmetoxybenzotiazolu na z
WO2016184381A1 (zh) 右旋奥拉西坦在制药领域中的应用
US6258807B1 (en) Method for treating pain
DE69612540T2 (de) Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von Krankheiten in Zusammenhang mit aktivem Sauestoff und freien Radikalen
DE69516110T2 (de) Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
EP0013252B1 (de) Mittel zur Senkung der Herzfrequenz
DE60307049T2 (de) Verwendung von Piperazin- Phenothiazin- Derivaten zur Herstellung eines Arzneimittels mit neuroprotektiven und/oder neurotropischen Wirkungen auf das ZNS und/oder PNS
EP1307195A2 (de) Cilansetron enthaltende arzneimittel zur behandlung nicht-obstipativer männlicher ibs-patienten
RU2248203C2 (ru) Церебропротекторное и ноотропное лекарственное средство "ноотрил" в таблетках, покрытых оболочкой
WO2003061654A1 (de) Pramipexol zur behandlung von hiv demenz
JPH0449231A (ja) 新規な分化誘導促進剤
SK279777B6 (sk) Použitie riluzolu na prípravu liečiva použiteľného
JPS58210019A (ja) 抗腫瘍剤

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20130225